RESUMO
Cells which are highly proliferative typically lack expression of differentiated, lineage-specific characteristics. Id2, a member of the helix-loop-helix (HLH) protein family known to inhibit cell differentiation, binds to the retinoblastoma protein (pRb) and abolishes its growth-suppressing activity. We found that Id2 but not Id1 or Id3 was able to bind in vitro not only pRb but also the related proteins p107 and p130. Also, an association between Id2 and p107 or p130 was observed in vivo in transiently transfected Saos-2 cells. In agreement with these results, expression of Id1 or Id3 did not affect the block of cell cycle progression mediated by pRb. Conversely, expression of Id2 specifically reversed the cell cycle arrest induced by each of the three members of the pRb family. Furthermore, the growth-suppressive activities of cyclin-dependent kinase inhibitors p16 and p21 were efficiently antagonized by high levels of Id2 but not by Id1 Id3. Consistent with the role of p16 as a selective inhibitor of pRb and pRb-related protein kinase activity, p16-imposed cell cycle arrest was completely abolished by Id2. Only a partial reversal of p21-induced growth suppression was observed, which correlated with the presence of a functional pRb. We also documented decreased levels of cyclin D1 protein and mRNA and the loss of cyclin D1-cdk4 complexes in cells constitutively expressing Id2. These data provide evidence for important Id2-mediated alterations in cell cycle components normally involved in the regulatory events of cell cycle progression, and they highlight a specific role for Id2 as an antagonist of multiple tumor suppressor proteins.
Assuntos
Ciclo Celular/fisiologia , Proteínas de Ligação a DNA/fisiologia , Proteínas de Neoplasias , Proteínas , Proteínas Proto-Oncogênicas , Proteínas Repressoras , Proteína do Retinoblastoma/fisiologia , Ciclina D1 , Quinase 4 Dependente de Ciclina , Quinases Ciclina-Dependentes/genética , Quinases Ciclina-Dependentes/fisiologia , Ciclinas/genética , Ciclinas/fisiologia , Proteínas de Ligação a DNA/genética , Sequências Hélice-Alça-Hélice , Humanos , Proteína 1 Inibidora de Diferenciação , Proteína 2 Inibidora de Diferenciação , Proteínas Inibidoras de Diferenciação , Proteínas Nucleares/antagonistas & inibidores , Proteínas Nucleares/fisiologia , Proteínas Oncogênicas/genética , Proteínas Oncogênicas/fisiologia , Fosfoproteínas/antagonistas & inibidores , Fosfoproteínas/fisiologia , Ligação Proteica , Proteína do Retinoblastoma/antagonistas & inibidores , Proteína p107 Retinoblastoma-Like , Proteína p130 Retinoblastoma-Like , Fatores de Transcrição/genética , Fatores de Transcrição/fisiologia , Transfecção , Células Tumorais CultivadasRESUMO
Recent evidence suggests that resistance to antineoplastic therapy may result from mutations in genes mediating the apoptotic response to DNA damage. To determine the effects of epigenetic changes on tumor responsiveness to cytotoxic agents inducing DNA damage, we examined the chemosensitivity of neuroblastoma (NB) after differentiation by retinoic acid (RA). Differentiation of the cell lines SH-SY5Y and SMS-KCNR by RA abolished the cytotoxic effects of adriamycin (Adr) and cisplatin. Chemoresistance was not the result of decreased proliferation induced by RA because: (a) growth arrest by nutrient deprivation did not affect sensitivity; (b) growth arrested NB cell lines, which did not differentiate, remained chemosensitive; and (c) RA concentrations which promoted differentiation without affecting growth, induced resistance. Apoptosis characterized NB cells responding to Adr, although differentiated SH-SY5Y did not apoptose and were resistant to Adr and cisplatin. Marked induction of bcl-2 in NB cells followed RA-induced differentiation, whereas in cell lines failing to differentiate, bcl-2 was not detected. Our data indicate that NB differentiation induces drug resistance after a loss of the apoptotic response to antineoplastic drugs and suggest that bcl-2 overexpression is an important mechanism of resistance in differentiated tumor cells.
Assuntos
Diferenciação Celular , Neuroblastoma/patologia , Proteínas Proto-Oncogênicas/metabolismo , Apoptose/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Doxorrubicina/toxicidade , Resistencia a Medicamentos Antineoplásicos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Genes myc , Humanos , Técnicas In Vitro , Neurônios/citologia , Proteínas Proto-Oncogênicas c-bcl-2 , RNA Mensageiro/genética , Tretinoína/farmacologia , Células Tumorais CultivadasRESUMO
The mechanisms of the uptake and release of m-iodobenzylguanidine (MIGB) have been studied in 5 neuroblastoma (NB) cell lines and in 4 clonal NB sublines with a homogeneous phenotype. A specific uptake system for MIBG was found in 8 of 9 NB cell lines or subpopulations. The uptake was characterized by temperature dependency, high affinity, saturability, sodium dependency, and imipramine sensitivity. The majority of NB cell lines that possessed a specific uptake system for MIBG were also able to efficiently store the incorporated drug. However, 3 NB cell lines were identified without the ability to retain high levels of MIBG, despite the presence of a specific uptake system. We also report that a clonal subline, SH-EP1, which has a nonneuroblastic phenotype, failed both MIBG uptake and retention. Conversely, the parental cell line, SK-N-SH, and the neuroblastic subline SH-SY5Y possessed both a specific uptake system and the ability to store MIBG. In addition, the induction of neuronal differentiation with retinoic acid increased the velocity of uptake and the storage efficiency for MIBG in the clonal subline SH-SY5Y. We conclude that MIBG uptake and storage should be considered to be frequent but independent neuronal functions of human NB cells.
Assuntos
Iodobenzenos/metabolismo , Neuroblastoma/metabolismo , 3-Iodobenzilguanidina , Transporte Biológico/efeitos dos fármacos , Diferenciação Celular , Imipramina/farmacologia , Técnicas In Vitro , Cinética , Sódio/metabolismo , Temperatura , Células Tumorais CultivadasRESUMO
A large body of evidence has been accumulated that demonstrates dominant effects of Id proteins on different aspects of cellular growth. Generally, constitutive expression of Id not only blocks cell differentiation but also drives proliferation. In some settings, it is sufficient to render cells immortal or induce oncogenic transformation. The participation of Id proteins in advanced human malignancy, where they are frequently deregulated, has been dramatically bolstered by the recent discovery that Id exert pivotal contributions to many of the essential alterations that collectively dictate malignant growth. Relentless proliferation associated with self-sufficiency in growth signals and insensitivity to growth inhibitory signals, sustained neoangiogenesis, tissue invasiveness and migration capabilities of tumor cells all share dependency on the unlimited availability of Id proteins. It is remarkable that many of these features recapitulate those physiologically propelled by Id proteins to support normal development. We propose that the participation of Id in multiple fundamental traits of cancer may be the basis for unprecedented therapeutic opportunities.
Assuntos
Transformação Celular Neoplásica/genética , Proteínas de Ligação a DNA/fisiologia , Regulação da Expressão Gênica no Desenvolvimento , Família Multigênica , Proteínas Repressoras , Fatores de Transcrição/fisiologia , Animais , Proteínas de Ciclo Celular/fisiologia , Divisão Celular/genética , Divisão Celular/fisiologia , Proteínas de Ligação a DNA/genética , Previsões , Regulação Neoplásica da Expressão Gênica , Genes do Retinoblastoma , Humanos , Proteína 1 Inibidora de Diferenciação , Proteína 2 Inibidora de Diferenciação , Proteínas Inibidoras de Diferenciação , Invasividade Neoplásica/genética , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/fisiologia , Neoplasias/genética , Neoplasias Experimentais/genética , Neoplasias de Tecido Nervoso/genética , Neovascularização Patológica/genética , Oncogenes , Proteína do Retinoblastoma/fisiologia , Transdução de Sinais , Fatores de Transcrição/genéticaRESUMO
Cranial irradiation (CI) is an effective way to prevent central nervous system (CNS) leukemia in children with acute leukemia (AL). However, it is still unclear whether the antileukemic effect of CI is mediated by alteration of blood-brain barrier (BBB) permeability and consequent increased levels of systemically administered drugs or whether it simply results from a direct cytolytic effect on leukemic cells in the meninges at diagnosis. We evaluated the influence of CI on BBB permeability to 1-beta-D-arabinofuranosylcytosine (ara-C) in 23 children with AL undergoing CI for CNS leukemia prophylaxis. CI was administered at 18 Gy (16 patients) and 24 Gy (7 patients). ara-C levels were measured in cerebrospinal fluid (CSF) and plasma before, during, and after CI. Two doses were evaluated: 75 mg/m2/day (12 patients) and 480 mg/m2/day (11 patients). CSF and plasma ara-C levels were measured when steady state was achieved. CSF:plasma ratios, obtained before, during, and after CI, were compared by an ANOVA model for repeated measures and by Tukey's test. At the 75-mg/m2/day dose, the mean values of ara-C CSF:plasma ratios before, during, and after CI were 0.20, 0.27, and 0.27, respectively. At the 480-mg/m2/day dose, the mean CSF:plasma ratios before, during, and after CI were 0.09, 0.12, and 0.13, respectively. No significant differences were observed when CSF:plasma ratios were compared before and during, during and after, and before and after CI. Our results indicate that CI at the doses used for CNS prophylaxis in AL does not significantly alter the BBB as far as ara-C is concerned.
Assuntos
Antimetabólitos Antineoplásicos/farmacocinética , Barreira Hematoencefálica/efeitos da radiação , Neoplasias Encefálicas/prevenção & controle , Irradiação Craniana , Citarabina/farmacocinética , Leucemia Mieloide Aguda/radioterapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/radioterapia , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , MasculinoRESUMO
Veno-occlusive disease of the liver (VOD) is an important complication in children with Wilms' tumour. Although in most patients this complication resolves uneventfully, fatal cases have been reported. Several observations strongly suggest that actinomycin-D is the likeliest cause of VOD in Wilms' tumour, but VOD seems to be rather uncommon in other malignancies treated with chemotherapy including actinomycin-D. The present case of VOD and the review of the literature stress the pathogenetic and clinical implications of VOD in the presence of a Wilms' tumour treated with actinomycin-D, originating in the right kidney. Greater awareness of this 'predisposing factor' may alert paediatricians to the presence of minimal signs of the syndrome.
Assuntos
Antibióticos Antineoplásicos/efeitos adversos , Dactinomicina/efeitos adversos , Hepatopatia Veno-Oclusiva/induzido quimicamente , Neoplasias Renais/tratamento farmacológico , Tumor de Wilms/tratamento farmacológico , Pré-Escolar , Humanos , Testes de Função Hepática , MasculinoRESUMO
[131I]metaiodobenzylguanidine ([131I]MIBG) is selectively taken up and stored by tumours derived from the neural crest, and is used for diagnosis and treatment of neuroblastoma (NB). The antitumoral effect of [131I]MIBG is closely related to the intracellular level of the radiopharmaceutical compound, which is dependent on uptake and storage/release mechanisms. While MIBG uptake is well characterised, storage and release mechanisms are still controversial. In order to better characterise [125I]MIBG release mechanisms, we studied the basal and stimulated efflux of [125I]MIBG in the human NB cell line, SH-SY5Y, preloaded with 0.1 microM [125I]MIBG for 1 h. We found that [125I]MIBG basal efflux is highly temperature-dependent, that [125I]MIBG release, induced by cell depolarisation with high potassium, is mainly calcium-independent, and induced by exchange with cold MIBG or noradrenaline, inversion of the sodium gradient across the cell membrane by veratridine by substitution of sodium chloride with equimolar concentration of lithium chloride. The exposure of NB cells to imipramine, an Uptake-1 inhibitor, also produces a net stimulatory effect on [125I]MIBG release. However, when used in association with other releasing stimuli, such as higher levels of intracellular sodium or external agonists, imipramine abolishes the consequent increase of [125I]MIBG release. Our findings suggest that stimulated [125I]MIBG release is mediated by a carrier, most probably the uptake carrier working in a reverse mode, while a minimal fraction of [125I]MIBG is released by an exocytotic mechanism.
Assuntos
Proteínas de Transporte/fisiologia , Iodobenzenos/farmacocinética , Neuroblastoma/metabolismo , 3-Iodobenzilguanidina , Transporte Biológico Ativo/efeitos dos fármacos , Humanos , Imipramina/farmacologia , Potássio/farmacologia , Temperatura , Células Tumorais CultivadasRESUMO
The outlook for disseminated neuroblastoma (NB) continues to be dismal. NB is a radiosensitive tumour. Owing to its high concentration in NB lesions, [131I]meta-iodobenzylguanidine [131I]MIBG has the potential for specifically delivering very large radiation doses to the malignant cells. Encouraging results have been reported with [131I]MIBG used alone in patients resistant to conventional therapy and at diagnosis. We report the first attempt to explore the integration of this new treatment modality with chemotherapy. Among the drugs effective in NB, cisplatin was chosen because of its high degree of activity against NB, its mild haematological toxicity and the known synergism between cisplatin and radiation. 4 patients, 3 with relapsed, heavily pre-treated, progressive stage IV NB, and 1 with stage IV NB at diagnosis, all with a good [131I]MIBG uptake, were investigated with combined therapy (CO-TH). Two complete remissions and one partial remission were observed in these patients 4-6 weeks following only a single course of both cisplatin and [131I]MIBG at "standard" dosage. The only toxicity was haematological, which was significant and relatively long-lasting, but was not associated with any serious infections or bleeding tendency. The general condition of these patients during the entire study period was excellent. The fourth patient, investigated at diagnosis with a modified less intensive treatment, obtained a partial remission with mild haematological toxicity. During the subsequent courses of intensive multidrug chemotherapy, this patient showed haematological toxicity comparable with that experienced by patients treated with an identical drug combination, but without previous treatment with CO-TH. The provisional conclusion of this ongoing study is that this new form of CO-TH appears most effective in obtaining a rapid and excellent response in heavily pretreated relapsed patients with progressive disease, and should be further investigated in earlier stages of the disease.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neuroblastoma/terapia , 3-Iodobenzilguanidina , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Pré-Escolar , Cisplatino/efeitos adversos , Cisplatino/uso terapêutico , Terapia Combinada , Doenças Hematológicas/etiologia , Humanos , Radioisótopos do Iodo/efeitos adversos , Radioisótopos do Iodo/uso terapêutico , Iodobenzenos/efeitos adversos , Iodobenzenos/uso terapêutico , Masculino , Neuroblastoma/tratamento farmacológico , Neuroblastoma/radioterapia , Projetos PilotoRESUMO
The combination of 131I-meta-iodobenzylguanidine (MIBG) with chemotherapy has recently been employed in the treatment of advanced stage neuroblastoma with encouraging results. However, the mechanisms underlying the interaction between these two different modalities of treatment have not yet been explored. In this study, human neuroblastoma cell lines pretreatment with cisplatin and doxorubicin increased cellular 125I-MIBG accumulation in a dose-dependent manner. Cell cycle analysis showed that increased 125I-MIBG accumulation correlated with the drug-induced G2/M phase block. Northern blot analysis demonstrated an increase in gene expression of the noradrenaline transporter induced by doxorubicin, but not by cisplatin treatment. Increased 125I-MIBG accumulation was also observed in murine xenografts of the human neuroblastoma cell line SK-N-DZ or BE(2)M17 treated intraperitoneally (i.p.) with cisplatin or doxorubicin, respectively. These results suggest that the combination of 131I-MIBG and these drugs could selectively increase radiation doses delivered to neuroblastomas.
Assuntos
3-Iodobenzilguanidina/farmacocinética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neuroblastoma/tratamento farmacológico , Compostos Radiofarmacêuticos/farmacocinética , Animais , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Northern Blotting , Cisplatino/administração & dosagem , Doxorrubicina/administração & dosagem , Citometria de Fluxo , Humanos , Masculino , Camundongos , Camundongos Nus , Transplante de Neoplasias , Neuroblastoma/metabolismo , Transplante Heterólogo , Células Tumorais Cultivadas/metabolismoRESUMO
The pharmacokinetics of carboplatin in cerebrospinal fluid (CSF) and plasma was studied in five children with brain tumors (four medulloblastomas and one ependimoblastoma) who underwent preirradiation treatment with carboplatin. Carboplatin pharmacokinetics was studied following the administration of 600 mg/m2 as a 1-h infusion. Four children were treated a few weeks after surgery, whereas one child with an unresectable tumor was treated prior to surgery. All patients had a ventricular-peritoneal CSF shunt connected to a subcutaneous reservoir. Total platinum and free carboplatin were measured. The mean AUC values for free carboplatin in CSF and plasma were 2.29 +/- 1.20 and 8.18 +/- 1.27 mg ml-1 min, respectively. The mean ratio of CSF AUC to plasma AUC was 0.28 (range, 0.17-0.46). Both plasma peak levels and AUC values showed limited interpatient variability. On the other hand, carboplatin levels in CSF showed substantial interpatient variability, with a greater than 5-fold difference in peak levels and a 3-fold difference in AUC values being recorded. The interpatient difference in CSF pharmacokinetics may have been related at least in part to the different anatomical alterations induced by the surgical procedures or by the presence of a large tumor mass. In the four evaluable patients exhibiting macroscopic residual tumor, we observed one complete remission (CR) and two partial remissions (PR) following two cycles that consisted of two doses of 600 mg/m2 carboplatin given on 2 consecutive days (total dose, 1200 mg/m2) and were separated by a 1-month interval. These results may give some indication as to the optimal dose and schedule for carboplatin administration in the treatment of primitive neuroectodermic tumors (PNET).
Assuntos
Neoplasias Encefálicas/líquido cefalorraquidiano , Cisplatino/líquido cefalorraquidiano , Neoplasias Encefálicas/sangue , Criança , Pré-Escolar , Cisplatino/sangue , Relação Dose-Resposta a Droga , Feminino , Humanos , Lactente , Infusões Intravenosas , MasculinoRESUMO
The present study was undertaken to evaluate in children the plasma pharmacokinetics of free carboplatin given at different doses and schedules and to evaluate the inter- and intrapatient variability and the possible influence of schedule on drug exposure. A total of 35 children (age range, 1-17 years) with malignant tumors were studied. All patients had normal renal function (creatinine clearance corrected for surface body area, above 70 ml min-1 m-2; range, 71-151 ml min-1 m-2) and none had renal involvement by malignancy. Carboplatin was given at the following doses and schedules: 175, 400, 500, and 600 mg/m2 given as as a 1-h infusion; 1,200 mg/m2 divided into equal doses and infused over 1 h on 2 consecutive days; and 875 and 1,200 mg/m2 given as a 5-day continuous infusion. A total of 57 courses were studied. Carboplatin levels in plasma ultrafiltrate (UF) samples were measured both by high-performance liquid chromatography and by atomic absorption spectrophotometry. Following a 1-h infusion, carboplatin free plasma levels decayed biphasically; the disappearance half-lives, total body clearance, and apparent volume of distribution were similar for different doses. In children with normal renal function as defined by creatinemia and blood urea nitrogen (BUN) and creatinine clearance, we found at each dose studied a limited interpatient variability of the peak plasma concentration (Cmax) and the area under the concentration-time curve (AUC) and a linear correlation between the dose and both Cmax (r = 0.95) and AUC (r = 0.97). The mean value +/- SD for the dose-normalized AUC was 13 +/- 2 min m2 l-1 (n = 57).2+ The administration schedule does not seem to influence drug exposure, since prolonged i.v. infusion or bolus administration of 1,200 mg/m2 achieved a similar AUC (13.78 +/- 2.90 and 15.05 +/- 1.44 mg ml-1 min, respectively). In the nine children studied during subsequent courses a limited interpatient variability was observed and no correlation (r = 0.035) was found between AUC and subsequent courses by a multivariate analysis of dose, AUC, and course number. The pharmacokinetic parameters were similar to those previously reported in adults; however, a weak correlation (r = 0.52, P = 0.03) between carboplatin total body clearance and creatinine clearance varying within the normal range was observed.(ABSTRACT TRUNCATED AT 400 WORDS)
Assuntos
Carboplatina/farmacocinética , Neoplasias/metabolismo , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Análise MultivariadaAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Neoplasias Retais/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Adulto , Idoso , Doxorrubicina/administração & dosagem , Avaliação de Medicamentos , Feminino , Fluoruracila/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Mitomicina , Mitomicinas/administração & dosagemRESUMO
Response to treatment is the most important prognostic factor in children undergoing treatment for acute lymphoblastic leukemia. Factors that interfere with the pharmacokinetic determinants of anti-leukemic compounds may cause a decreased activity of one or more of the drugs included in the treatment protocol. Noncompliance with the prescribed treatment, individual pharmacokinetic differences, interference with oral drug absorption, and different guidelines for dose reduction related to toxicity are some of the factors responsible for a decreased or variable antileukemic activity which may influence treatment results.
Assuntos
Antineoplásicos/metabolismo , Leucemia Linfoide/tratamento farmacológico , Antineoplásicos/uso terapêutico , Disponibilidade Biológica , Relação Dose-Resposta a Droga , Humanos , Individualidade , Absorção Intestinal , Cinética , Mercaptopurina/metabolismo , Metotrexato/metabolismo , Cooperação do Paciente , PrognósticoRESUMO
Retinoic acid (RA) induces cell cycle arrest and differentiation of human neuroblastoma (NB) cells. Typically, NB cells differentiate along the neuronal lineage, but quiescent, "flat" cell types frequently have been described after treatment with differentiating agents. Two indistinguishable subclones of the cell line SK-N-SH, SK-N-SH-N (SH-N) and SK-N-SH-F (SH-F), display dramatically different responses to RA. In SH-N, RA induces neuronal differentiation, but in SH-F it transforms the small neuroblastic cells into large, flattened, epithelium-like cells. Here we analyze the mechanistic basis for the different effects of RA in the two NB subclones. First, we show that the flattened RA-treated SH-F expresses markers of cells undergoing replicative senescence. Inhibition of DNA synthesis by RA is significantly more rapid in SH-F than in SH-N. SH-F, which expresses basal amounts of p16(INK4A), responds to RA with elevation of p18(INK4C), marked down-regulation of cyclin D1, and swift inhibition of cyclin D-dependent kinases (cdks). Conversely, after addition of RA, SH-N retains cell cycling due to high expression of cyclin D1, the absence of Ink4 inhibitors, and accumulation of p21(Cip1). These changes result in sustained cdk activity. Accordingly, overexpression of p21(Cip1) but not p16(INK4A) induces neuronal differentiation of untreated NB cells. We propose that rapid inhibition of cdks by RA in NB leads to early cell cycle arrest, prevents neuronal differentiation, and results in a senescence-like state.
Assuntos
Ciclo Celular/efeitos dos fármacos , Diferenciação Celular/fisiologia , Senescência Celular/fisiologia , Neuroblastoma/patologia , Linhagem Celular , Inibidor p16 de Quinase Dependente de Ciclina/genética , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , Inibidor de Quinase Dependente de Ciclina p21 , Ciclinas/metabolismo , Humanos , RNA Mensageiro/genética , Tretinoína/farmacologiaRESUMO
We measured 6-mercaptopurine levels in the cerebrospinal fluid and plasma of 15 children undergoing treatment for acute leukemia. Plasma and cerebrospinal fluid samples obtained by lumbar puncture were collected before, during, and after cranial irradiation in order to evaluate a possible change in blood-brain barrier permeability to orally administered 6-mercaptopurine. Considerable interpatient variability has been observed in both plasma and cerebrospinal fluid 6-mercaptopurine levels. No statistical differences in the 6-mercaptopurine cerebrospinal fluid levels under the three different conditions could be detected. Our data suggest that cranial irradiation does not significantly influence the cerebrospinal fluid levels.
Assuntos
Encéfalo/efeitos da radiação , Mercaptopurina/líquido cefalorraquidiano , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Administração Oral , Adolescente , Barreira Hematoencefálica/efeitos da radiação , Encéfalo/metabolismo , Criança , Pré-Escolar , Cromatografia Líquida de Alta Pressão , Feminino , Humanos , Masculino , Mercaptopurina/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Fatores de TempoRESUMO
[131I]Metaiodobenzylguanidine (131I-MIBG) is selectively taken up and stored by tumors derived from the neural crest and is utilized in the diagnosis and treatment of neuroblastoma (NB). Variable MIBG uptake has been observed, although the underlying mechanisms are not known. We have studied the uptake kinetics of 125I-MIBG and uptake characteristics of NB cell clones with different phenotypes (SH-SY5Y and SH-EP1, the neuroblastic and the substrate-adherent sublines of SK-N-SH respectively, BE(2)-M17 and LA-N-1n with neuroblastic phenotype). We have been able to correlate the MIBG uptake with the neuroblastic phenotype: a specific uptake system satisfying all the characteristics of the neuronal uptake-1 (temperature dependency, sodium dependency, high affinity, saturability and imipramine sensitivity) was observed in all the neuroblastic sublines. In contrast, MIBG accumulation was a passive diffusion phenomenon in the substrate-adherent clone SH-EP1. In addition, terminal neuronal differentiation induced in SH-SY5Y by retinoic acid caused a marked increase of the uptake and retention of MIBG. Our findings may be pertinent to an understanding of the variability of the MIBG uptake in vivo.
Assuntos
Antineoplásicos/farmacocinética , Iodobenzenos/farmacocinética , Neuroblastoma/metabolismo , 3-Iodobenzilguanidina , Humanos , Técnicas In Vitro , Radioisótopos do Iodo , Células Tumorais CultivadasRESUMO
Eleven cases of neuroblastoma (10 males and 1 female; 9 aged 1-13 years, and two aged 17 and 38 years, respectively) ten of which were refractory to chemotherapy, were submitted to treatment with [131I]metaiodobenzylguanidine (131I-MIBG). The therapeutic procedure consisted essentially of single doses (2.6-9.5 GBq) of 131I-MIBG mostly split into two parts, administered by slow i.v. infusion and given in several therapeutic courses, usually at 1-2 month intervals. The treatment resulted in: 1 complete response, 1 partial response, 1 minor response, 4 stabilized diseases and 2 progressive diseases (two patients were not evaluable due to rapid progression of the disease). Pain relief was observed in all cases and particularly in four patients who suffered severe tumor pain. The major side-effects recorded were: hypertensive crises over a 6-day period in one case, fever lasting a few days in another and bone marrow depression in two intensively pretreated patients. A slight hematologic toxicity was observed, however, in almost all cases.
Assuntos
Antineoplásicos/uso terapêutico , Radioisótopos do Iodo/uso terapêutico , Iodobenzenos/uso terapêutico , Neuroblastoma/terapia , 3-Iodobenzilguanidina , Adolescente , Adulto , Criança , Pré-Escolar , Terapia Combinada , Feminino , Humanos , Lactente , MasculinoRESUMO
Treatment of resistant neuroblastoma with high dosage [131I]metaiodobenzylguanidine (131I-MIBG) appears effective since encouraging results have been obtained so far even in patients with very advanced, intensively pre-treated disease. We have already reported a stage III NB patient treated at diagnosis, who is at present in complete remission with a 4-year follow-up. To further explore the potential role of this new drug in untreated patients, we administered radionuclide to two children with stage III neuroblastoma. Both cases received 131I-MIBG at relatively low doses, and showed a significant reduction of the tumor mass and, interestingly enough, no evidence of 131I-MIBG uptake of a tracer dose in the remaining tumor. Particularly in case 1, the permanence and subsequent progression of the part of the tumor mass without 131I-MIBG uptake, after therapeutic doses of 131I-MIBG which apparently destroyed the 131I-MIBG-positive cell population, clearly suggest heterogeneity at diagnosis, with a dual neuroblastoma cell population, one with 131I-MIBG uptake and the other without. Aside from the biological implications of the heterogeneous MIBG uptake in neuroblastoma at diagnosis, our findings suggest that in stage III neuroblastoma patients even a relatively small dose of 131I-MIBG administered at diagnosis is sufficient to either completely destroy the primary tumor, as reported by our group, or to destroy that part of the tumor which shows 131I-MIBG uptake (as in the present cases), without any significant hematologic toxicity. Furthermore, a single course of 131I-MIBG at the dosage employed here does not appear to jeopardize the subsequent use of chemotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Antineoplásicos/uso terapêutico , Radioisótopos do Iodo/uso terapêutico , Iodobenzenos/uso terapêutico , Neuroblastoma/terapia , 3-Iodobenzilguanidina , Pré-Escolar , Terapia Combinada , Feminino , Humanos , Neuroblastoma/diagnóstico por imagem , CintilografiaRESUMO
Plasma levels of 6-mercaptopurine (6-MP) were measured after oral administration in 17 children with acute lymphoblastic leukemia (ALL). In the fasting state or after a breakfast consisting of 250 ml milk and 50 g biscuits, 6-MP was administered at a dose of 75 mg/m2. In patients studied in a fasting state, the mean time to plasma peak (tmax) level was 1.2 h, whereas in patient studied after breakfast the mean tmax was 2.3 h. This difference is statistically significant (p less than 0.001). Moreover, the 6-MP peak plasma concentration (cmax) and the areas under the plasma concentration time curves (AUC) were significantly reduced when the drug was administered after breakfast. The mean Cmax +/- SD were 0.98 +/- 0.54 microM and 0.63 +/- 0.48 microM, respectively (p less than 0.05). The mean 6-MP AUC +/- SD in patients studied in a fasting state and after breakfast were 143 +/- 69 microM min and 105 +/- 68 microM, respectively (p less than 0.01). These results indicated that 6-MP should be taken in a fasting state to optimize drug absorption in children undergoing chemotherapy for ALL.